1. Scrip
  2. >>Business

Roche’s Polivy Set For Blockbuster Sales After Frontline Lymphoma Success

First Progress In Frontline DLBCL In 20 Years

 
• By Andrew McConaghie

Roche has not disclosed the full data yet, but is confident that Polivy can surpass CAR-Ts and other competitors to be the new standard of care.

Roche_Basel
While CAR-Ts grabbed the headlines when launched several years ago, Roche's Polivy looks set to have a greater impact on DLBCL treatment.

Roche’s Polivy in combination with chemotherapy could become the new standard first line therapy in diffuse large B-cell lymphoma (DLBCL) after significantly improving progression-free survival compared with standard treatment – the first time this has been achieved in 20 years.

The company announced the news from its Phase III POLARIX trial on 9 August, but revealed no further details

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.